
Quarterly report 2025-Q3
added 11-12-2025
BioCardia Market Cap 2011-2026 | BCDA
As of March 18, 2026 BioCardia has a market cap of $ 27.1 M
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap BioCardia
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8.9 M | 37 M | 31.3 M | 51.9 M | 29 M | 58 M | 99.2 M | 79.3 M | 18.4 M | 25.3 M | 18.4 M | 16.1 M | 20.7 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 99.2 M | 8.9 M | 38 M |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Biotechnology industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
ARCA biopharma
ABIO
|
484 M | - | 1052.0 % | $ 415 M | ||
|
MorphoSys AG
MOR
|
315 M | - | 2.43 % | $ 254 M | ||
|
Acorda Therapeutics
ACOR
|
16.7 M | - | -24.86 % | $ 820 K | ||
|
AbCellera Biologics
ABCL
|
962 M | $ 3.55 | -0.28 % | $ 1.06 B | ||
|
Adagene
ADAG
|
87.8 M | $ 3.91 | -2.01 % | $ 220 M | ||
|
Acasti Pharma
ACST
|
40.7 M | - | 4.01 % | $ 150 M | ||
|
AC Immune SA
ACIU
|
305 M | $ 3.32 | 6.07 % | $ 229 M | ||
|
I-Mab
IMAB
|
127 M | - | - | $ 866 M | ||
|
Advaxis
ADXS
|
1.87 M | - | -9.65 % | $ 45.9 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
33.6 B | - | - | $ 40.3 B | ||
|
Biophytis SA
BPTS
|
549 M | - | -13.47 % | $ 169 M | ||
|
Aeterna Zentaris
AEZS
|
41.4 M | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
14.1 K | - | -10.17 % | $ 12.2 K | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
28.9 M | - | -1.52 % | $ 24.7 M | ||
|
ADC Therapeutics SA
ADCT
|
1.22 B | $ 4.11 | -2.61 % | $ 105 M | ||
|
Aeglea BioTherapeutics
AGLE
|
724 M | - | - | $ 1.01 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
32.8 M | - | - | $ 26.5 M | ||
|
Aptorum Group Limited
APM
|
4.09 M | $ 0.79 | 0.04 % | $ 4.31 M | ||
|
Midatech Pharma plc
MTP
|
79 M | - | -18.52 % | $ 27.3 M | ||
|
Adverum Biotechnologies
ADVM
|
76.4 M | - | - | $ 86.2 M | ||
|
argenx SE
ARGX
|
13.8 B | $ 706.03 | 0.39 % | $ 25 B | ||
|
Alterity Therapeutics Limited
ATHE
|
895 M | $ 3.34 | -7.48 % | $ 8.04 B | ||
|
Ascendis Pharma A/S
ASND
|
7.37 B | $ 228.06 | -1.28 % | $ 5 B | ||
|
Akero Therapeutics
AKRO
|
3.25 B | - | - | $ 3.67 B | ||
|
Akouos
AKUS
|
172 M | - | 0.23 % | $ 488 M | ||
|
Институт стволовых клеток человека
ISKJ
|
2.83 B | - | - | - | ||
|
Albireo Pharma
ALBO
|
538 M | - | -0.23 % | $ 916 M | ||
|
Acer Therapeutics
ACER
|
12.1 M | - | 2.71 % | $ 14 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
3.16 B | $ 3.43 | -4.19 % | $ 7.46 B | ||
|
Allena Pharmaceuticals
ALNA
|
71.4 M | - | 3.16 % | $ 1.9 M | ||
|
Aileron Therapeutics
ALRN
|
38.2 M | - | 10.36 % | $ 9.8 M | ||
|
AlloVir
ALVR
|
13.1 M | - | 4.14 % | $ 49.1 M | ||
|
Anika Therapeutics
ANIK
|
373 M | $ 14.51 | 1.04 % | $ 213 M | ||
|
Aptinyx
APTX
|
9.48 M | - | -39.0 % | $ 4.57 M | ||
|
Applied Molecular Transport
AMTI
|
22.1 M | - | - | $ 10.1 M | ||
|
Aptose Biosciences
APTO
|
2.32 M | - | -45.71 % | $ 1.2 M | ||
|
Arcturus Therapeutics Holdings
ARCT
|
217 M | $ 6.39 | -3.62 % | $ 175 M | ||
|
BioNTech SE
BNTX
|
62.9 B | $ 94.86 | 4.77 % | $ 27.2 B | ||
|
CureVac N.V.
CVAC
|
3.53 B | - | - | $ 867 M | ||
|
Aravive
ARAV
|
60.4 M | - | -13.39 % | $ 1.45 M | ||
|
Burford Capital Limited
BUR
|
2.09 B | $ 8.28 | 2.86 % | $ 1.34 B | ||
|
Athira Pharma
ATHA
|
16.2 M | - | - | $ 269 M | ||
|
Athersys
ATHX
|
364 M | - | 3.77 % | $ 22.4 M | ||
|
Actinium Pharmaceuticals
ATNM
|
48.4 M | $ 1.14 | 2.7 % | $ 34.3 M | ||
|
Avenue Therapeutics
ATXI
|
544 K | - | -52.27 % | $ 4.45 M | ||
|
Autolus Therapeutics plc
AUTL
|
424 M | $ 1.51 | - | $ 385 M | ||
|
AVEO Pharmaceuticals
AVEO
|
98 M | - | - | $ 521 M | ||
|
Atea Pharmaceuticals
AVIR
|
426 M | $ 6.13 | 1.32 % | $ 500 M | ||
|
AVROBIO
AVRO
|
56.3 M | - | 1083.1 % | $ 745 M | ||
|
Equillium
EQ
|
84.7 M | $ 2.15 | -7.33 % | $ 74.7 M |